Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis Wan-chin KuoJennifer M. StevensLisa C. Bratzke Nonstatin Drugs ( M. Vrablik, Section Editor) 07 July 2020 Article: 30
Management of Structural Heart Disease and Acute Coronary Syndromes in the COVID-19 Pandemic Arturo GiordanoGiuseppe Biondi-ZoccaiAntonio L. Bartorelli Commentary 10 June 2020 Article: 29
Periodontal Inflammation and the Risk of Cardiovascular Disease Aditi PriyamvaraAmit K. DeyCarl J. Lavie Coronary Heart Disease (S. Virani and S. Naderi, Section Editor) 08 June 2020 Article: 28
Statin Intolerance in Clinical Practice Michaela SnejdrlovaT. AltschmiedovaR. Ceska Statin Drugs (R. Ceska, Section Editor) 03 June 2020 Article: 27
Clinical Pharmacology of Statins: an Update Nicola FerriAlberto Corsini Statin Drugs (R. Ceska, Section Editor) 03 June 2020 Article: 26
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions Aliza HussainChristie M. BallantyneSalim S Virani Coronary Heart Disease (S. Virani and S. Naderi, Section Editor) 03 June 2020 Article: 25
New Pharmacological Approaches to Target PCSK9 Alberico L. CatapanoAngela PirilloGiuseppe D. Norata Nonstatin Drugs (M. Vrablik, Section Editor) 03 June 2020 Article: 24